Novartis AG Receives Positive Results For Ofatumumab In Phase III Multiple Sclerosis Studies

Novartis AG (LSE:0QLR) has received positive results for ofatumumab (OMB157) from the Phase III ASCLEPIOS I and II studies evaluating the safety and efficacy of ofatumumab 20mg monthly subcutaneous injections over Aubagio®14mg daily oral tablets. Ofatumumab demonstrated superiority over Aubagio® (teriflunomide) in patients with relapsing forms of multiple sclerosis (RMS), in both head-to-head studies.